| Heatherdowns Rehab & Residential Center | |
| 2401 Cass Rd, Toledo, Ohio 43614 | |
| (419) 382-5050 | |
| Name | Heatherdowns Rehab & Residential Center |
|---|---|
| Location | 2401 Cass Rd, Toledo, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 84 |
| Occupancy Rate | 67.02% |
| Medicare ID (CCN) | 365737 |
| Legal Business Name | Heatherdowns Operating Company Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1427684091 |
| Organization Name | MAJESTIC CARE OF MAUMEE LLC |
| Address | 2401 Cass Rd, Toledo, OH 43614 |
| Phone Number | 419-382-5050 |
News Archive
UCL scientists have discovered the key brain region for navigating well-known places, helping explain why brain damage seen in early stages of Alzheimer's disease can cause such severe disorientation.
Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has cleared its CONTOUR Next EZ, a new blood glucose monitoring (BGM) system for use in the United States.
MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.
› Verified 5 days ago
| NPI Number | 1538233283 |
| Organization Name | HEALTHCARE VENTURES OF OHIO LLC |
| Doing Business As | HEATHERDOWNS REHAB & RESIDENTIAL CTR |
| Address | 2401 Cass Rd, Toledo, OH 43614 |
| Phone Number | 419-382-5050 |
News Archive
UCL scientists have discovered the key brain region for navigating well-known places, helping explain why brain damage seen in early stages of Alzheimer's disease can cause such severe disorientation.
Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has cleared its CONTOUR Next EZ, a new blood glucose monitoring (BGM) system for use in the United States.
MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.
› Verified 5 days ago
| NPI Number | 1568088995 |
| Organization Name | HEATHERDOWNS OPERATING COMPANY LLC |
| Address | 2401 Cass Rd, Toledo, OH 43614 |
| Phone Number | 419-382-5050 |
News Archive
UCL scientists have discovered the key brain region for navigating well-known places, helping explain why brain damage seen in early stages of Alzheimer's disease can cause such severe disorientation.
Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has cleared its CONTOUR Next EZ, a new blood glucose monitoring (BGM) system for use in the United States.
MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
UCL scientists have discovered the key brain region for navigating well-known places, helping explain why brain damage seen in early stages of Alzheimer's disease can cause such severe disorientation.
Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has cleared its CONTOUR Next EZ, a new blood glucose monitoring (BGM) system for use in the United States.
MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 25.28 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 14.59 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 39.19 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.63 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.58 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 31.29 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.96 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 97.55 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 20 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 90 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.79 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 34.3 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.1 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.03 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.76 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 67.91 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 79.09 | 82.93 |
News Archive
UCL scientists have discovered the key brain region for navigating well-known places, helping explain why brain damage seen in early stages of Alzheimer's disease can cause such severe disorientation.
Researchers at the Louisiana State University Health Sciences Center have figured out how ATP is broken down in cells, providing for the first time a clear picture of the key reaction that allows cells in all living things to function and flourish.
SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug.
Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has cleared its CONTOUR Next EZ, a new blood glucose monitoring (BGM) system for use in the United States.
MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.
› Verified 5 days ago
Park Terrace Nursing And Rehabilitation Center Location: 2735 Darlington Rd, Toledo, Ohio 43606 Phone: (419) 531-4465 | |
Heatherdowns Rehab & Residential Center Location: 2401 Cass Rd, Toledo, Ohio 43614 Phone: (419) 382-5050 |